Treatment Algorithm for Lung Cancer Bone Metastases
Author Information
Author(s): Lim Ah Reum, Yoon Won Sup, Park Sunmin, Rim Chai Hong
Primary Institution: Korea University Ansan Hospital
Hypothesis
What are the key prognostic factors influencing the survival of patients with lung cancer bone metastases?
Conclusion
The study developed a treatment algorithm that emphasizes personalized and collaborative care for managing lung cancer bone metastases.
Supporting Evidence
- Bone metastases significantly affect the quality of life and prognosis in lung cancer patients.
- Key prognostic factors include EGFR mutation status, ECOG performance, and systemic therapy use.
- The median survival for patients with lung cancer bone metastases ranged from 1.8 to 28.3 months.
Takeaway
This study helps doctors figure out the best way to treat lung cancer patients with bone problems by looking at many different factors.
Methodology
The study reviewed 15 studies published after 2000, analyzing survival factors in lung cancer patients with bone metastases.
Potential Biases
Most studies included were non-randomized, which may introduce bias.
Limitations
The proposed algorithm is based on meta-analysis results and expert opinions, requiring validation through independent patient data.
Participant Demographics
The studies included patients with lung cancer bone metastases from various countries, with a median age range of 57 to 70 years.
Statistical Information
P-Value
<0.1
Confidence Interval
1.345–3.305
Statistical Significance
p<0.1
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website